LY3322207

LY3322207 is a small molecule drug that was developed by Eli Lilly for the treatment of cardiovascular diseases, specifically targeting hypertension. The drug reached Phase 1 clinical trials but development was discontinued. Its mechanism of action and molecular target have not been publicly disclosed in available sources. Clinical studies focused on evaluating its safety, tolerability, and pharmacokinetics in healthy subjects and patients with hypertension who were already receiving angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARB)[1][2][4]. No further development or approval has been reported.